Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gross Profit (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Gross Profit for 5 consecutive years, with $181.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 73.15% year-over-year to $181.2 million, compared with a TTM value of $599.9 million through Dec 2025, up 65.57%, and an annual FY2025 reading of $599.9 million, up 65.57% over the prior year.
  • Gross Profit was $181.2 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $160.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $181.2 million in Q4 2025 and bottomed at -$155.0 million in Q4 2022.
  • Average Gross Profit over 5 years is $71.5 million, with a median of $73.8 million recorded in 2023.
  • The sharpest move saw Gross Profit tumbled 769.77% in 2022, then soared 190.63% in 2023.
  • Year by year, Gross Profit stood at $23.1 million in 2021, then crashed by 769.77% to -$155.0 million in 2022, then soared by 147.62% to $73.8 million in 2023, then skyrocketed by 41.77% to $104.6 million in 2024, then surged by 73.15% to $181.2 million in 2025.
  • Business Quant data shows Gross Profit for KNSA at $181.2 million in Q4 2025, $160.6 million in Q3 2025, and $138.2 million in Q2 2025.